Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Original Research

Accepted on 17 Mar 2025

Preclinical studies of a PARP targeted theranostic radiopharmaceutical for pancreatic cancer

in Pharmacology of Anti-Cancer Drugs

Jie Gao
Yu-Hao Wang
Ruoqi Wang
Mengya Liu
Hongliang Wang
Jianguo Li
Jin Du

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1576587

157 views

Editorial

Published on 17 Mar 2025

Editorial: Drugs and methods that enhance the anti-cancer efficacy of artesunate

in Pharmacology of Anti-Cancer Drugs

Tuğçenur Uzun

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1566700

501 views

Original Research

Published on 17 Mar 2025

Onvansertib exhibits anti-proliferative and anti-invasive effects in endometrial cancer

in Pharmacology of Anti-Cancer Drugs

Nikita Sinha
Xiaochang Shen
Jennifer Haag
Shuning Chen
Haomeng Zhang
Catherine John
Wenchuan Sun
Michael Emanuele
Chunxiao Zhou
Victoria Bae-Jump

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1545038

741 views

Original Research

Published on 17 Mar 2025

Metformin upregulates circadian gene PER2 to inhibit growth and enhance the sensitivity of glioblastoma cell lines to radiotherapy via SIRT2/G6PD pathway

in Pharmacology of Anti-Cancer Drugs

Hailiang Li
Zheng Ma
Wanfu Yang
Yifan Zhang
Jinping Sun
Haifeng Jiang
Faxuan Wang
Li Hou
Hechun Xia

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1563865

897 views

Review

Published on 17 Mar 2025

Potential role of lactylation in intrinsic immune pathways in lung cancer

in Pharmacology of Anti-Cancer Drugs

Mengdie Huang
Ye Jin
Dandan Zhao
Xingren Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1533493

1,263 views

Review

Published on 17 Mar 2025

Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients

in Pharmacology of Anti-Cancer Drugs

Chao Min
Xiong Zhong
Yue Cui
Hanfu Zhang
Qingming Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1515555

957 views

Original Research

Published on 14 Mar 2025

SB218078 inhibits angiogenesis and epithelial-mesenchymal transition in breast cancer

in Pharmacology of Anti-Cancer Drugs

Qianxue Wu
Jiawei Xu
Xin Tang
Jin Yu
Benhua Li
Jun Yang
Xiang Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1552707

562 views

Correction

Published on 14 Mar 2025

Corrigendum: LINC-PINT suppresses cisplatin resistance in gastric cancer by inhibiting autophagy activation via epigenetic silencing of ATG5 by EZH2

in Pharmacology of Anti-Cancer Drugs

Cheng Zhang
Tong Kang
Xinyi Wang
Jizhao Wang
Lin Liu
Jiawei Zhang
Xu Liu
Rong Li
Jiansheng Wang
Jia Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1424320

445 views

Original Research

Accepted on 13 Mar 2025

Hypothyroidism as a Predictive Biomarker for Survival Benefits in Advanced Colorectal Cancer Patients Treated with Apatinib-Based Therapy

in Pharmacology of Anti-Cancer Drugs

Yi Zhong
Jingyi Wu
Fang Guo
Shuang Dong
Xiaoyu Li
Xianmin Zhu
Yuze Zhu
Kun Wang
Yuanxiang Li
Sheng Hu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1506830

101 views

Systematic Review

Published on 13 Mar 2025

Adverse kidney related events following targeted therapies in lung cancer: a systematic review and network meta-analysis of randomized controlled trials

in Pharmacology of Anti-Cancer Drugs

Song Ren
Wei Wang
Xiaoxiu Yao
Wenyan Fang
Guisen Li
Yunlin Feng
Min Xia

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1511171

680 views

Original Research

Published on 12 Mar 2025

Prediction of neoadjuvant chemotherapy efficacy and prognostic biomarker analysis in patients with triple-negative breast cancer

in Pharmacology of Anti-Cancer Drugs

Xiao-Wen Liao
Jia-Bin Gao
Hong Sun
Hong-Dan Chen
Min-Hui Zheng
Lei Han
Xiao-Geng Chen
Yu-Nan Su
Ding-Long Pan
Min Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1553831

675 views

Editorial

Published on 11 Mar 2025

Editorial: Metabolic reprogramming in cancer

in Pharmacology of Anti-Cancer Drugs

Valentina Audrito
Elisa Giovannetti

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1583986

489 views

Original Research

Published on 11 Mar 2025

Gut microbiota-derived metabolite phenylacetylglutamine inhibits the progression of prostate cancer by suppressing the Wnt/β-catenin signaling pathway

in Pharmacology of Anti-Cancer Drugs

Jing Lv
Shengkai Jin
Yuhua Zhou
Chaowei Fu
Yang Shen
Bo Liu
Jufa Li
Menglu Li
Yuwei Zhang
Ninghan Feng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1528058

808 views

Original Research

Published on 11 Mar 2025

Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database

in Pharmacology of Anti-Cancer Drugs

Jing Shi
Xinya Liu
Mengjiao Gao
Jian Yu
Ting Chai
Yun Jiang
Jiawei Li
Yuanming Zhang
Li Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1519849

898 views

Case Report

Published on 10 Mar 2025

Case Report: A novel MET exon 14 skipping mutation after EGFR-TKI resistance in advanced lung adenocarcinoma and sustained clinical response to savolitinib

in Pharmacology of Anti-Cancer Drugs

Yinyin Xue
Wen Li
Pengfei Li
Kaili Huang
Qinghua Zhou
Qiang Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1489696

536 views

Review

Published on 10 Mar 2025

TCR-T cell therapy for solid tumors: challenges and emerging solutions

in Pharmacology of Anti-Cancer Drugs

Wanjun He
Kai Cui
Muhammad Asad Farooq
Na Huang
Songshan Zhu
Dan Jiang
Xiqian Zhang
Jian Chen
Yinxia Liu
Guangxian Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1493346

1,178 views